CRISPR Diagnostic Patents

CRISPR diagnostic patents cover collateral-cleavage detection innovations; Cas-enzyme and guide-RNA innovations; amplification and readout innovations; and multiplexing and point-of-care innovations — with IP held by the two CRISPR-diagnostics pioneers (whose dispute parallels the broader CRISPR patent fight) and others. THE MECHANISM: certain CRISPR enzymes (Cas12, Cas13, Cas14) exhibit 'COLLATERAL' (trans) cleavage — once the Cas-guide complex recognizes its specific target nucleic acid, the enzyme becomes a non-specific nuclease that chews up nearby REPORTER molecules (a quenched fluorophore or a lateral-flow reporter), producing a detectable signal — turning CRISPR into a sequence-specific diagnostic. MAJOR CRISPR-DIAGNOSTIC PATENT HOLDERS: MAMMOTH BIOSCIENCES (Jennifer Doudna / UC Berkeley): DETECTR (DNA Endonuclease Targeted CRISPR Trans Reporter) using Cas12a (and Cas14/CasΦ) collateral cleavage, and a deep Cas-protein-discovery + diagnostics estate. SHERLOCK BIOSCIENCES (Feng Zhang / Broad Institute): SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) using Cas13 collateral RNA cleavage with isothermal amplification, plus INSPECTR (amplification-free). OTHERS: Caspr Biotech, and academic/licensing holders — and notably, the Mammoth-vs-Sherlock split mirrors the Broad-vs-Berkeley CRISPR patent dispute (the underlying Cas IP is contested). Collateral-cleavage detection, Cas enzymes/guides, amplification integration, and point-of-care readout are the core CRISPR-diagnostic patent domains — COVID-19 (where SHERLOCK/DETECTR got the first CRISPR-diagnostic FDA authorizations) accelerated the field.

Collateral-cleavage detection innovations; Cas-enzyme discovery and engineering innovations; guide-RNA and target innovations; and reporter and signal innovations represent core CRISPR-diagnostic patent domains — and the collateral-cleavage detection scheme plus the specific Cas enzyme are the foundational, contested inventions. COLLATERAL-CLEAVAGE PATENTS: the diagnostic scheme itself — using a Cas enzyme's target-activated non-specific (collateral/trans) cleavage to cut reporter molecules and generate signal upon detecting a specific sequence (the foundational Broad/Berkeley patents covering this for Cas13/Cas12 are valuable and disputed). CAS-ENZYME PATENTS: the specific Cas enzymes — Cas12a (Cpf1), Cas13 (RNA-targeting, multiple subtypes), Cas14/Cas12f and CasΦ (compact enzymes — Mammoth's discovery program finds new, smaller, or more-specific enzymes), and engineered Cas variants for sensitivity/specificity; novel Cas-enzyme discovery is a key, defensible composition area. GUIDE-RNA / TARGET PATENTS: guide-RNA design for a target, multiplexed guides, and target-sequence selection (for pathogens, mutations, or biomarkers). REPORTER / SIGNAL PATENTS: reporter chemistry (fluorescent, lateral-flow, colorimetric, electrochemical), signal amplification, and quantification. SPECIFICITY PATENTS: single-nucleotide specificity (distinguishing point mutations/variants — important for genotyping/variant detection). The collateral-cleavage detection scheme (foundational, contested) and novel Cas-enzyme discovery (compact/specific enzymes) are the highest-value CRISPR-diagnostic IP.

Isothermal-amplification-integration innovations; sample-to-answer and point-of-care innovations; multiplexing innovations; and amplification-free and sensitivity innovations represent additional CRISPR-diagnostic patent domains — and making the assay sensitive, fast, and field-deployable is what turns the mechanism into a usable test. AMPLIFICATION-INTEGRATION PATENTS: combining CRISPR detection with ISOTHERMAL amplification (boosting sensitivity without a thermocycler) — recombinase polymerase amplification RPA, loop-mediated isothermal amplification LAMP, and one-pot/single-reaction integration of amplification + CRISPR detection (a key practical challenge — combining the steps without interference); the amplification + CRISPR integration is valuable, patentable process IP. POINT-OF-CARE / SAMPLE-TO-ANSWER PATENTS: integrating sample prep, amplification, CRISPR reaction, and readout into a simple device/cartridge (lateral-flow strip, microfluidic chip) for use without a lab (the COVID use case), minimal-equipment readout, and rapid time-to-result. MULTIPLEXING PATENTS: detecting many targets in one reaction (different Cas enzymes/guides with distinguishable reporters — e.g. a panel of pathogens or variants), and combinatorial barcoding. AMPLIFICATION-FREE / SENSITIVITY PATENTS: achieving clinically-useful sensitivity WITHOUT amplification (simpler, faster — Sherlock's INSPECTR and signal-amplification approaches), and enzyme/reporter engineering for sensitivity. Isothermal-amplification integration, sample-to-answer point-of-care cartridges, and amplification-free sensitivity are the highest-value applied CRISPR-diagnostic IP because they determine whether the test works in the field.

CRISPR diagnostic startup IP strategy must navigate the foundational collateral-cleavage and Cas-protein patents (split between Broad/Sherlock and Berkeley/Mammoth — and contested, like the broader CRISPR dispute, so the underlying Cas IP you use may be claimed by one or both), isothermal-amplification prior art (RPA/LAMP are pre-existing, some with their own IP — e.g. RPA/TwistDx), §101 limits on detection methods (a bare 'detect a sequence' claim is vulnerable, but detection tied to the specific Cas collateral-cleavage mechanism is more defensible), FDA/CLIA diagnostic regulation, and a landscape where the specific enzyme, the assay integration, and point-of-care deployment are the durable assets; understand that the foundational mechanism is contested-and-licensed, that the durable startup IP is in NOVEL Cas-enzyme discovery, amplification integration, point-of-care/sample-to-answer design, multiplexing, and amplification-free sensitivity, and that FDA clearance and assay performance matter as much as patents; identify whitespace in novel compact Cas enzymes, one-pot integration, point-of-care, and amplification-free detection. CRISPR-DIAGNOSTIC STARTUP IP STRATEGY: THE FOUNDATIONAL MECHANISM IS CONTESTED-AND-LICENSED — NOVEL ENZYMES, INTEGRATION, AND POC ARE THE IP: collateral cleavage and core Cas proteins are foundationally held (Broad/Sherlock and Berkeley/Mammoth, contested like the CRISPR dispute) — clear FTO/licensing, then patent NOVEL Cas-enzyme discovery, amplification integration, sample-to-answer design, and multiplexing; NOVEL COMPACT/SPECIFIC Cas ENZYMES ARE HIGHEST-VALUE WHITESPACE: discovering new, smaller, or more-specific Cas enzymes (Cas14/CasΦ-style) sidesteps the contested mainstream IP and is composition-of-matter; ONE-POT AMPLIFICATION INTEGRATION AND POINT-OF-CARE ARE THE PRACTICAL FRONTIER: combining isothermal amplification + CRISPR in a single, simple, field-deployable cartridge (the make-or-break usability problem) is valuable, patentable process/device IP; AMPLIFICATION-FREE SENSITIVITY IS A DIFFERENTIATING GOAL: achieving clinical sensitivity without amplification (simpler/faster) is a high-value, open area; TIE DETECTION TO THE Cas MECHANISM FOR §101: claim the assay as a specific Cas-collateral-cleavage process, not a bare 'detect a sequence' method; FDA/CLIA CLEARANCE AND PERFORMANCE ARE PARALLEL MOATS: regulatory authorization and demonstrated sensitivity/specificity gate the market; WHEN TO PATENT: NOVEL ENZYME/ASSAY WITH MEASURED PERFORMANCE: file once a system shows measured results (limit of detection + sensitivity/specificity + time-to-result + multiplexing + amplification-free? + point-of-care usability) vs. SHERLOCK/DETECTR/PCR baselines — measured LOD, sensitivity/specificity, time-to-result, and usability are the critical CRISPR-diagnostic IP metrics; KEY FTO CHECKLIST: Mammoth DETECTR Cas12a/Cas14/CasΦ collateral cleavage (Doudna/Berkeley); Sherlock SHERLOCK Cas13 + RPA, INSPECTR amplification-free (Zhang/Broad); collateral/trans cleavage detection scheme (Broad vs Berkeley contested); novel Cas-enzyme discovery composition; guide-RNA design/multiplexed/single-nucleotide specificity; reporter fluorescent/lateral-flow/electrochemical; RPA/LAMP isothermal amplification (TwistDx RPA IP) + one-pot integration; sample-to-answer cartridge point-of-care; amplification-free sensitivity; detection §101-tied-to-Cas-mechanism; FDA/CLIA.